373692009: Substance with phosphodiesterase inhibitor mechanism of action (substance)

SNOMED CT Concept\Substance\Substance categorized by disposition\Substance with effector mechanism of action (substance)\Enzyme inhibitor\Hydrolase inhibitor\Phosphodiesterase inhibitor

Status: current, Sufficiently defined by necessary conditions definition status (core metadata concept). Date: 31-Jan 2018. Module: SNOMED CT core

Descriptions:

Expanded Value Set

Outbound Relationships	Type	Target	Active	Characteristic	Refinability	Group	Values
Phosphodiesterase inhibitor	Is a	Inotropic agent (substance)	false	Inferred relationship	Some
Phosphodiesterase inhibitor	Is a	Enzyme inhibitor	false	Inferred relationship	Some
Phosphodiesterase inhibitor	Is a	Hydrolase inhibitor	true	Inferred relationship	Some
Phosphodiesterase inhibitor	This attribute specifies the behavior that a substance will exhibit or participate in, given the appropriate context.	Phosphodiesterase inhibitor (disposition)	true	Inferred relationship	Some

Inbound Relationships	Type	Active	Source	Characteristic	Refinability	Group
Milrinone (substance)	Is a	False	Phosphodiesterase inhibitor	Inferred relationship	Some
Phosphodiesterase inhibitor poisoning	Causative agent	True	Phosphodiesterase inhibitor	Inferred relationship	Some	1
Accidental phosphodiesterase inhibitor poisoning	Causative agent	False	Phosphodiesterase inhibitor	Inferred relationship	Some
Intentional phosphodiesterase inhibitor poisoning	Causative agent	False	Phosphodiesterase inhibitor	Inferred relationship	Some
forgiftning med phosphodiesterasehæmmer, uvist med hvilken hensigt	Causative agent	False	Phosphodiesterase inhibitor	Inferred relationship	Some	2
Phosphodiesterase inhibitor adverse reaction	Causative agent	True	Phosphodiesterase inhibitor	Inferred relationship	Some	1
Allergy to phosphodiesterase inhibitor	Causative agent	False	Phosphodiesterase inhibitor	Inferred relationship	Some
Phosphodiesterase inhibitor overdose	Causative agent	True	Phosphodiesterase inhibitor	Inferred relationship	Some	1
Accidental phosphodiesterase inhibitor overdose	Causative agent	True	Phosphodiesterase inhibitor	Inferred relationship	Some	1
Intentional phosphodiesterase inhibitor overdose	Causative agent	True	Phosphodiesterase inhibitor	Inferred relationship	Some	1
overdosis af phosphodiesterasehæmmer, uvist med hvilken hensigt	Causative agent	False	Phosphodiesterase inhibitor	Inferred relationship	Some	1
Product containing phosphodiesterase inhibitor (product)	The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications.	True	Phosphodiesterase inhibitor	Inferred relationship	Some	1
Enoximone (substance)	Is a	False	Phosphodiesterase inhibitor	Inferred relationship	Some
Cilostazol	Is a	False	Phosphodiesterase inhibitor	Inferred relationship	Some
Phosphodiesterase 5 inhibitor	Is a	True	Phosphodiesterase inhibitor	Inferred relationship	Some
Theophylline (substance)	Is a	True	Phosphodiesterase inhibitor	Inferred relationship	Some
Amrinone	Is a	False	Phosphodiesterase inhibitor	Inferred relationship	Some
Aminophylline 100 mg oral tablet	The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications.	False	Phosphodiesterase inhibitor	Inferred relationship	Some
aminophyllin 25 mg/ml injektionsvæske, opløsning, ampul a 10 ml	The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications.	False	Phosphodiesterase inhibitor	Inferred relationship	Some
aminophyllin 225 mg tablet med modificeret udløsning	The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications.	False	Phosphodiesterase inhibitor	Inferred relationship	Some
aminophyllin 350 mg tablet med modificeret udløsning	The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications.	False	Phosphodiesterase inhibitor	Inferred relationship	Some
aminophyllin 100 mg tablet med modificeret udløsning	The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications.	False	Phosphodiesterase inhibitor	Inferred relationship	Some
aminophyllin 25 mg/ml injektionsvæske, opløsning i fyldt injektionssprøjte a 10 ml	The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications.	False	Phosphodiesterase inhibitor	Inferred relationship	Some
Caffeine solution	The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications.	False	Phosphodiesterase inhibitor	Inferred relationship	Some
Product containing precisely caffeine 100 milligram and ergotamine tartrate 1 milligram/1 each conventional release oral tablet (clinical drug)	The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications.	False	Phosphodiesterase inhibitor	Inferred relationship	Some
Caffeine 100 mg and ergotamine tartrate 2 mg rectal suppository	The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications.	False	Phosphodiesterase inhibitor	Inferred relationship	Some
Product containing xanthine (product)	The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications.	False	Phosphodiesterase inhibitor	Inferred relationship	Some
Aminophylline-containing product in oral dose form	The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications.	False	Phosphodiesterase inhibitor	Inferred relationship	Some
Aminophylline-containing product in parenteral dose form	The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications.	False	Phosphodiesterase inhibitor	Inferred relationship	Some
caffein 5 mg/ml injektionsvæske, opløsning, hætteglas a 2 ml	The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications.	False	Phosphodiesterase inhibitor	Inferred relationship	Some
koffein og natriumbenzoat injektionsvæske, opløsning, hætteglas	The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications.	False	Phosphodiesterase inhibitor	Inferred relationship	Some
Product containing aminophylline (medicinal product)	The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications.	False	Phosphodiesterase inhibitor	Inferred relationship	Some
Product containing caffeine (medicinal product)	The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications.	False	Phosphodiesterase inhibitor	Inferred relationship	Some
paracetamol + caffein + dihydrocodeinbitartrat	The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications.	False	Phosphodiesterase inhibitor	Inferred relationship	Some
xanthinbronchodilatorer	The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications.	False	Phosphodiesterase inhibitor	Inferred relationship	Some
Product containing aspirin and caffeine and cinnamedrine (medicinal product)	The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications.	False	Phosphodiesterase inhibitor	Inferred relationship	Some
Product containing aspirin and caffeine and orphenadrine (medicinal product)	The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications.	False	Phosphodiesterase inhibitor	Inferred relationship	Some
Product containing caffeine and paracetamol and salicylamide (medicinal product)	The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications.	False	Phosphodiesterase inhibitor	Inferred relationship	Some
Product containing buffered aspirin and caffeine (medicinal product)	The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications.	False	Phosphodiesterase inhibitor	Inferred relationship	Some
Product containing aspirin and caffeine and paracetamol (medicinal product)	The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications.	False	Phosphodiesterase inhibitor	Inferred relationship	Some
Product containing aspirin and caffeine (medicinal product)	The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications.	False	Phosphodiesterase inhibitor	Inferred relationship	Some
Product containing precisely aspirin 389 milligram and caffeine 32.4 milligram and dextropropoxyphene hydrochloride 32 milligram/1 each conventional release oral capsule (clinical drug)	The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications.	False	Phosphodiesterase inhibitor	Inferred relationship	Some
Butalbital 50 mg and caffeine 40 mg and codeine phosphate 30 mg and paracetamol 325 mg oral capsule	The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications.	False	Phosphodiesterase inhibitor	Inferred relationship	Some
Aspirin 325 mg and butalbital 50 mg and caffeine 40 mg and codeine phosphate 30 mg oral capsule	The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications.	False	Phosphodiesterase inhibitor	Inferred relationship	Some
dyphyllin 125 mg/ml injektionsvæske, opløsning, ampul a 2 ml	The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications.	False	Phosphodiesterase inhibitor	Inferred relationship	Some
dyphyllin 160 mg/15 ml eliksir	The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications.	False	Phosphodiesterase inhibitor	Inferred relationship	Some
dyphyllin 100 mg/15 ml eliksir	The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications.	False	Phosphodiesterase inhibitor	Inferred relationship	Some
Diprophylline 200 mg oral tablet	The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications.	False	Phosphodiesterase inhibitor	Inferred relationship	Some
Diprophylline 400 mg oral tablet	The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications.	False	Phosphodiesterase inhibitor	Inferred relationship	Some
caffeincitrat 20 mg/ml injektionsvæske, opløsning, ampul	The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications.	False	Phosphodiesterase inhibitor	Inferred relationship	Some
Caffeine citrate 20mg solution	The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications.	False	Phosphodiesterase inhibitor	Inferred relationship	Some
Product containing precisely butalbital 50 milligram and caffeine 40 milligram and paracetamol 325 milligram/1 each conventional release oral capsule (clinical drug)	The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications.	False	Phosphodiesterase inhibitor	Inferred relationship	Some
Product containing precisely butalbital 50 milligram and caffeine 40 milligram and paracetamol 325 milligram/1 each conventional release oral tablet (clinical drug)	The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications.	False	Phosphodiesterase inhibitor	Inferred relationship	Some
Product containing precisely butalbital 50 milligram and caffeine 40 milligram and paracetamol 500 milligram/1 each conventional release oral capsule (clinical drug)	The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications.	False	Phosphodiesterase inhibitor	Inferred relationship	Some
Product containing precisely butalbital 50 milligram and caffeine 40 milligram and paracetamol 500 milligram/1 each conventional release oral tablet (clinical drug)	The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications.	False	Phosphodiesterase inhibitor	Inferred relationship	Some
Caffeine 30 mg and dihydrocodeine tartrate 16 mg and paracetamol 356.4 mg oral capsule	The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications.	False	Phosphodiesterase inhibitor	Inferred relationship	Some
Product containing precisely caffeine 60 milligram and dihydrocodeine tartrate 32 milligram and paracetamol 712.8 milligram/1 each conventional release oral tablet (clinical drug)	The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications.	False	Phosphodiesterase inhibitor	Inferred relationship	Some
Product containing precisely caffeine 100 milligram and isometheptene mucate 65 milligram and paracetamol 325 milligram/1 each conventional release oral capsule (clinical drug)	The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications.	False	Phosphodiesterase inhibitor	Inferred relationship	Some
Product containing precisely aspirin 325 milligram and butalbital 50 milligram and caffeine 40 milligram/1 each conventional release oral capsule (clinical drug)	The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications.	False	Phosphodiesterase inhibitor	Inferred relationship	Some
Aspirin 325 mg and butalbital 50 mg and caffeine 40 mg oral tablet	The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications.	False	Phosphodiesterase inhibitor	Inferred relationship	Some
Product containing precisely aspirin 356.4 milligram and caffeine 30 milligram and dihydrocodeine tartrate 16 milligram/1 each conventional release oral capsule (clinical drug)	The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications.	False	Phosphodiesterase inhibitor	Inferred relationship	Some
Aspirin 385 mg and caffeine 30 mg and orphenadrine citrate 25 mg oral tablet	The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications.	False	Phosphodiesterase inhibitor	Inferred relationship	Some
Aspirin 428 mg and caffeine 30 mg and orphenadrine citrate 25 mg oral tablet	The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications.	False	Phosphodiesterase inhibitor	Inferred relationship	Some
Aspirin 770 mg and caffeine 60 mg and orphenadrine citrate 50 mg oral tablet	The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications.	False	Phosphodiesterase inhibitor	Inferred relationship	Some
Aspirin 856 mg and caffeine 60 mg and orphenadrine citrate 50 mg oral tablet	The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications.	False	Phosphodiesterase inhibitor	Inferred relationship	Some
Aspirin 389 mg and caffeine 32.4 mg and dextropropoxyphene hydrochloride 65 mg oral capsule	The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications.	False	Phosphodiesterase inhibitor	Inferred relationship	Some
dyphyllin 100 mg + guaifenesin 100 mg eliksir	The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications.	False	Phosphodiesterase inhibitor	Inferred relationship	Some
dyphyllin 100 mg + guaifenesin 100 mg væske	The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications.	False	Phosphodiesterase inhibitor	Inferred relationship	Some
dyphyllin 100 mg + guaifenesin 100 mg syrup	The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications.	False	Phosphodiesterase inhibitor	Inferred relationship	Some
Diprophylline 100 mg and guaifenesin 100 mg oral tablet	The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications.	False	Phosphodiesterase inhibitor	Inferred relationship	Some
dyphyllin 100 mg + guaifenesin 50 mg syrup	The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications.	False	Phosphodiesterase inhibitor	Inferred relationship	Some
Diprophylline 200 mg and guaifenesin 100 mg oral capsule	The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications.	False	Phosphodiesterase inhibitor	Inferred relationship	Some
Diprophylline 200 mg and guaifenesin 200 mg oral tablet	The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications.	False	Phosphodiesterase inhibitor	Inferred relationship	Some
aminophyllin 25 mg/ml injektionsvæske, opløsning, hætteglas a 10 ml	The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications.	False	Phosphodiesterase inhibitor	Inferred relationship	Some
aminophyllin 25 mg/ml injektionsvæske, opløsning, ampul a 10 ml	The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications.	False	Phosphodiesterase inhibitor	Inferred relationship	Some
aminophyllin 250 mg/10 ml injektionsvæske, ampul a 20 ml	The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications.	False	Phosphodiesterase inhibitor	Inferred relationship	Some
Product containing diprophylline (medicinal product)	The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications.	False	Phosphodiesterase inhibitor	Inferred relationship	Some
acetylsalicylsyre + caffein + orphenadrincitrat tablet	The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications.	False	Phosphodiesterase inhibitor	Inferred relationship	Some
Product containing caffeine in oral dose form (medicinal product form)	The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications.	False	Phosphodiesterase inhibitor	Inferred relationship	Some
Caffeine-containing product in rectal dose form	The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications.	False	Phosphodiesterase inhibitor	Inferred relationship	Some
Product containing caffeine in parenteral dose form (medicinal product form)	The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications.	False	Phosphodiesterase inhibitor	Inferred relationship	Some
aminophyllin tablet med modificeret udløsning	The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications.	False	Phosphodiesterase inhibitor	Inferred relationship	Some
Aminophylline-containing product in rectal dose form	The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications.	False	Phosphodiesterase inhibitor	Inferred relationship	Some
Aminophylline 250 mg rectal suppository	The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications.	False	Phosphodiesterase inhibitor	Inferred relationship	Some
Product containing precisely aminophylline 500 milligram/1 each conventional release rectal suppository (clinical drug)	The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications.	False	Phosphodiesterase inhibitor	Inferred relationship	Some
Aminophylline 200 mg oral tablet	The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications.	False	Phosphodiesterase inhibitor	Inferred relationship	Some
aminophyllin 105 mg/5 ml oral væske	The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications.	False	Phosphodiesterase inhibitor	Inferred relationship	Some
Product containing diprophylline in oral dose form (medicinal product form)	The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications.	False	Phosphodiesterase inhibitor	Inferred relationship	Some
Diprophylline-containing product in parenteral dose form	The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications.	False	Phosphodiesterase inhibitor	Inferred relationship	Some
dyphyllin 300 mg + guaifenesin 300 mg væske	The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications.	False	Phosphodiesterase inhibitor	Inferred relationship	Some
acetylsalicylsyre + butalbital + caffein + codeinphosphat	The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications.	False	Phosphodiesterase inhibitor	Inferred relationship	Some
paracetamol + caffein + isometheptenmucat	The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications.	False	Phosphodiesterase inhibitor	Inferred relationship	Some
Product containing diprophylline and guaifenesin (medicinal product)	The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications.	False	Phosphodiesterase inhibitor	Inferred relationship	Some
acetylsalicylsyre + caffein + propoxyphenhydrochlorid	The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications.	False	Phosphodiesterase inhibitor	Inferred relationship	Some
acetylsalicylsyre + caffein + dihydrocodeinbitartrat	The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications.	False	Phosphodiesterase inhibitor	Inferred relationship	Some
Caffeine + ergotamine tartrate	The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications.	False	Phosphodiesterase inhibitor	Inferred relationship	Some
Product containing caffeine and sodium benzoate (medicinal product)	The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications.	False	Phosphodiesterase inhibitor	Inferred relationship	Some
Product containing butalbital and caffeine and paracetamol (medicinal product)	The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications.	False	Phosphodiesterase inhibitor	Inferred relationship	Some
acetylsalicylsyre + caffein + orphenadrincitrat	The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications.	False	Phosphodiesterase inhibitor	Inferred relationship	Some
paracetamol + butalbital + caffein + codeinphosphat	The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications.	False	Phosphodiesterase inhibitor	Inferred relationship	Some
Product containing aspirin and butalbital and caffeine (medicinal product)	The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications.	False	Phosphodiesterase inhibitor	Inferred relationship	Some

Page 1 of 2 End

This concept is not in any reference sets

Back to Start

Id	Description	Lang	Type	Status	Case?	Module
1212151018	Phosphodiesterase inhibitor	en	Synonym (core metadata concept)	Active	Entire term case insensitive (core metadata concept)	SNOMED CT core
3520795018	Substance with phosphodiesterase inhibitor mechanism of action (substance)	en	Fully specified name	Active	Entire term case insensitive (core metadata concept)	SNOMED CT core
3520964015	Substance with phosphodiesterase inhibitor mechanism of action	en	Synonym (core metadata concept)	Active	Entire term case insensitive (core metadata concept)	SNOMED CT core
4496211000005116	phosphodiesterasehæmmer	da	Synonym (core metadata concept)	Active	Entire term case insensitive (core metadata concept)	Danish module (core metadata concept)